"
IMT504: A New and Potent Adjuvant for Rabies Vaccines Permitting Significant Dose Sparing"
written by Alejandro D. Montaner, Analia De Nichilo, Juan M. Rodriguez, Andres Hernando-Insua, Juan Fló, Ricardo A. Lopez, Verónica Sierra, Claudio Paolazzi, Oscar Larghi, David L. Horn, Jorge Zorzopulos, Fernanda Elias,
published by
World Journal of Vaccines,
Vol.2 No.4, 2012
has been cited by the following article(s):
|
[1]
|
History of Rabies in the Americas: From the Pre-Columbian to the Present, Volume I
Fascinating Life Sciences,
2023
DOI:10.1007/978-3-031-25052-1_2
|
|
|
|
|
[2]
|
Rabies
2020
DOI:10.1016/B978-0-12-818705-0.00014-5
|
|
|
|
|
[3]
|
Single-stranded oligodeoxynucleotides induce plant defence in Arabidopsis thaliana
Annals of Botany,
2020
DOI:10.1093/aob/mcaa061
|
|
|
|
|
[4]
|
Antibody Response Following Pre-Exposure Immunization Against Rabies in High-Risk Professionals
Vector-Borne and Zoonotic Diseases,
2019
DOI:10.1089/vbz.2019.2526
|
|
|
|
|
[5]
|
Rabies – epidemiology, pathogenesis, public health concerns and advances in diagnosis and control: a comprehensive review
Veterinary Quarterly,
2017
DOI:10.1080/01652176.2017.1343516
|
|
|
|
|
[6]
|
Antiviral Therapy for Human Rabies
Antiviral Therapy,
2015
DOI:10.3851/IMP2851
|
|
|
|
|
[7]
|
Non-Clinical Safety Studies of IMT504, a Unique Non-CpG Oligonucleotide
Nucleic Acid Therapeutics,
2014
DOI:10.1089/nat.2013.0479
|
|
|
|